Adjunctive TBO-309 added to stroke clot removal treatment safety
Treatments studied
Part of Brain & nervous system, Heart & circulation clinical trials.
This Phase 2 trial studies whether adding TBO-309 to standard emergency treatment for acute ischemic stroke is safe and tolerable. It may help researchers see if the added drug can be given without causing excessive side effects alongside clot-busting and/or clot-removal procedures.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have had an acute ischemic stroke (a stroke caused by a blocked artery).
- You will receive standard emergency treatment: either IV clot-busting (alteplase or tenecteplase) and confirmed by a CT scan, and/or clot removal through a catheter (endovascular thrombectomy) for a specific type/location of blockage.
- Your stroke impact is at least mild (NIHSS score 5 or higher), and your expected pre-stroke independence was good (pre-stroke mRS less than 4).
- You must be treated within the time window your stroke team determines (within 6 hours, or 6–24 hours from “last known well” if scans suggest salvageable brain tissue).
- You must have no major reasons the study drug would be unsafe, including: recent bleeding in the brain, recent heart attack or stroke, uncontrolled very high blood pressure, inability to get consent, or a strong chance you’ll need stents plus extra blood thinners.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding the anti-clotting drug tirofiban to standard clot removal for people who have a stroke due to a narrowed artery in the brain. The goal is to see if this combination improves outcomes without raising bleeding risk.
This trial tests whether adding a second medicine (tirofiban) to standard clot-busting treatment can help people who are not improving after the first hour. It is for people with a moderate to severe stroke who are not candidates for a clot-removal procedure.
This Phase 2 trial tests whether the study medicine (LT3001) is safe and improves outcomes for people with an acute ischemic stroke who are getting a procedure to remove a clot (EVT). It aims to help certain patients who have a specific brain scan pattern soon after stroke symptoms start.
This trial tests whether giving a clot-dissolving medication directly into the brain's blood vessels during a standard procedure (mechanical thrombectomy) can improve outcomes for people with a stroke caused by a blockage in a medium-sized artery. It may be an option for patients who arrive at the hospital within 24 hours of symptom onset and have enough salvageable brain tissue.
This trial tests if removing a large blood clot from the brain up to 3 days after a stroke improves recovery compared to standard medical care alone. It is for patients who have a severe stroke and are otherwise healthy enough for the procedure.
This trial tests a new clot-busting medicine called tenecteplase, given directly into the blood vessel in the brain, to treat strokes caused by a blockage in a medium-sized artery. The goal is to see if it can help restore blood flow and reduce disability, especially for patients who can be treated within 24 hours of stroke onset.
Hear when a new Acute Ischemic Stroke trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.